By David Sachs A Bayer-owned drug developer received special fast-track status from U.S. regulators for its Parkinson s disease treatment following positive phase-1 trials. The German.
Bayer announced on Thursday that the U.S. FDA has granted Regenerative Medicine Advanced Therapy designation to the experimental Parkinson s disease treatment currently being developed by its.
LEVERKUSEN (dpa-AFX) - German pharmaceutical and life sciences major Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday that its clinical stage cell therapy unit BlueRock Therapeutics LP's